MedTrace Logo

Rituximab for Pulmonary Sarcoidosis

NCT00855205 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2013-12-11

No results posted yet for this study

Summary

Sarcoidosis is a inflammatory disease affecting many parts of the body, especially the lungs. While most patients do well, there is a group of patients who require continuous doses of prednisone or other drugs. The current study will determine the role of Rituximab as new agent for patients with refractory disease.

Conditions

  • Sarcoidosis

Interventions

DRUG

Rituximab

Rituximab will be administered by IV infusion at a dose of 1000 mg (1 g) on day 1 and 15

Sponsors & Collaborators

  • University of Chicago

    collaborator OTHER

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Robert P Baughman, MD · University of Cincinnati

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00855205 on ClinicalTrials.gov